IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 4, Pages e002460
Publisher
BMJ
Online
2021-04-21
DOI
10.1136/jitc-2021-002460
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- (2020) Laura Strauss et al. Science Immunology
- Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function
- (2020) Elham Beyranvand Nejad et al. INTERNATIONAL JOURNAL OF CANCER
- Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
- (2020) Marit van Elsas et al. Journal for ImmunoTherapy of Cancer
- Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
- (2020) Elham Beyranvand Nejad et al. Journal for ImmunoTherapy of Cancer
- Interleukin 6 (IL-6) promotes Brucella abortus clearance by controlling bactericidal activity of macrophages and CD8+ T cell differentiation
- (2019) Huynh Tan Hop et al. INFECTION AND IMMUNITY
- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy
- (2018) Lukasz Bialkowski et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
- (2018) Jibin Li et al. MEDICAL SCIENCE MONITOR
- Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement
- (2016) Rashmi Bharti et al. CANCER LETTERS
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
- (2016) Sylvia Heink et al. NATURE IMMUNOLOGY
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site
- (2015) Maxime Thoreau et al. Oncotarget
- Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
- (2015) T. C. van der Sluis et al. Cancer Immunology Research
- Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation
- (2014) Ceri A. Fielding et al. IMMUNITY
- Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis
- (2014) JAN SOMMER et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and functionin vitroandin vivo
- (2013) Christina E. Arnold et al. IMMUNOLOGY
- Cytokine patterns in patients with cancer: a systematic review
- (2013) Bodo E Lippitz LANCET ONCOLOGY
- Critical and Independent Role for SOCS3 in Either Myeloid or T Cells in Resistance to Mycobacterium tuberculosis
- (2013) Berit Carow et al. PLoS Pathogens
- Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors
- (2012) S. van Duikeren et al. JOURNAL OF IMMUNOLOGY
- Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2
- (2012) Sharon Cohen et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- A Critical Role for SOCS3 in Innate Resistance to Toxoplasma gondii
- (2011) Ryan J. Whitmarsh et al. Cell Host & Microbe
- Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
- (2011) Jermaine Coward et al. CLINICAL CANCER RESEARCH
- Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells
- (2010) Yue Wang et al. CANCER LETTERS
- Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo
- (2009) Roland Axmann et al. ARTHRITIS AND RHEUMATISM
- The immunologic constant of rejection
- (2008) Ena Wang et al. TRENDS IN IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search